An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals.
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Albinterferon alfa 2B (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 17 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.